UBS Remains a Hold on Northern Star Resources Ltd (NESRF)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spry covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Perseus Mining , and Evolution Mining . According to TipRanks, Spry has an average return of 11.3% and a 65.58% success rate on recommended stocks.
In addition to UBS, Northern Star Resources Ltd also received a Hold from J.P. Morgan's Al Harvey in a report issued yesterday. However, today, Macquarie maintained a Buy rating on Northern Star Resources Ltd (Other OTC: NESRF).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
an hour ago
UK Supreme Court quashes convictions of 2 bank traders after deciding their trials were unfair
LONDON -- Britain's Supreme Court on Wednesday quashed the convictions of two financial market traders accused of manipulating benchmark interest rates in one of the biggest scandals to come out of the global financial crisis in 2008. The charges against Tom Hayes, a former Citigroup and UBS trader, and Carlo Palombo, who worked for Barclays, centered around alleged efforts to influence the London Inter-Bank Offered Rate, or Libor, and its euro currency equivalent Euribor, which were used to set the interest rates on trillions of dollars of loans and other financial products around the world. The court ruled that the convictions of Hayes and Palombo were unfair because the judges in their separate cases gave inaccurate instructions to jurors. That effectively prevented jurors from considering the key question of whether the traders had acted dishonestly. 'That misdirection undermined the fairness of the trial,' Judge George Leggatt wrote in an 82-page decision backed by all five members of the panel that heard the case. Hayes was convicted in August 2015 and sentenced to a maximum of 14 years in prison, which was later reduced to 11 years. Palombo, convicted in March 2019, was sentenced to four years in prison. Both men were released in 2021. 'It destroyed my family, I missed most of my son's childhood,' Hayes told the BBC. 'For so long I've been an international fugitive … and now I can move on with my life, or try to,' he added. The decision came after the U.S. Second Circuit Court of Appeal in 2022 overturned the convictions of two traders charged with similar crimes in the United States. Hayes and Palombo, whose appeals were repeatedly rejected by British judges, were allowed to take their case to the U.K. Supreme Court after that ruling. The U.K.'s Serious Fraud Office began investigating alleged efforts to manipulate Libor in 2012. That ultimately led to the conviction of nine bankers. 'We have considered this judgment and the full circumstances carefully and determined it would not be in the public interest for us to seek a retrial,' the SFO said in response to the Supreme Court ruling. Libor and Euribor were critical benchmarks that were once used to set the interest rates on everything from business loans to home mortgages and credit card debts. As a result, they also became central to more complex financial transactions such as those used by banks and businesses to bet on interest rate fluctuations. The benchmarks were vulnerable to manipulation because they were set by banks that could profit from swings in interest rates. Each day, major international banks were asked to submit the interest rate at which they could borrow money from other banks. An average of those submissions was then used to set the daily Libor and Euribor rates. During the financial crisis, regulators became aware that some banks were making artificially low Libor submissions to make their institutions seem more creditworthy. Some traders also sought to influence the submissions made by their banks as even small moves in the benchmark rates could boost their profits. Those risks became even more pronounced during the financial crisis, when lending dried up and bankers had to base their daily submissions on a subjective assessment of the market rather than actual loans.
Yahoo
2 hours ago
- Yahoo
Pinterest Rallies on User Surge and Global Ad Expansion Success
Pinterest, Inc. (NYSE:PINS) is one of the . The company bustles with analyst ratings and price target changes, following strong Q1 results and successful Ad tool adoption. A young, stylish woman using her smartphone to find inspiration for her latest DIY project. San Francisco-based company, Pinterest, Inc. (NYSE:PINS) is a visual discovery engine and social media platform. The company, with its smartphone application and web platforms, enables users to find, save, and shop ideas via virtual pinboards. From recipes and home decor to fashion and travel, the company's database holds a wide range of collections to meet the needs of its users. On May 8, 2025, the company released its Q1 2025 results. It indicated a record number of 570 million monthly active users (MAUs) across the globe and a 16% year-over-year increase in revenue. The company's Performance+ ad tool helped with the expansion of its lower-funnel shopping playbook internationally. As a result, the ad revenue for the quarter in Europe and other regions around the world went up by over 3 times faster than overall revenue growth in those areas. Recently, following these developments, UBS and KeyBanc raised their price targets on the stock, while maintaining a Buy rating and an Overweight rating, respectively. UBS raised the price target from $44 to $50 while KeyBanc elevated it from $40 to $45 as of July 17, 2025. Pinterest, Inc. (NYSE:PINS) offers a blend of low risk and high growth with its beta of 0.77 and a five-year anticipated EPS growth of 24.68%. While we acknowledge the potential of PINS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Exelixis Gains Analyst Confidence as Cancer Studies Advances
Exelixis, Inc. (NASDAQ:EXEL) is one of the . The company advances its studies following a significant rise in price targets from analysts. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Based in California, Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on discovering, developing, and commercializing oncology medicines. It is known for its work in oncology, specifically with small-molecule therapies and antibody-drug conjugates. The company's key products include CABOMETYX (cabozantinib) and COMETRIQ. With these products, the company targets difficult-to-treat cancers such as renal cell and medullary thyroid carcinoma. On June 10, 2025, Barclays, while keeping an Equal Weight rating on the stock, raised its price target from $29 to $40. Reflecting the sentiment, UBS also raised its price target on the stock from $38 to $43, while maintaining a Neutral rating. With the new price targets indicating confidence in the company's progress, Exelixis, Inc. (NASDAQ:EXEL) provided updates on its ongoing clinical studies. Study of XL092 has entered Phase 3, where its efficiency with nivolumab is tested in comparison to sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who have not received prior systemic anticancer therapy. The company also announced a Phase 1 clinical study on XL309 to estimate its safety and preliminary efficacy, both alone and in combination with olaparib, in treating advanced solid tumors. In addition to these advances in cancer treatment, investors are also intrigued by the company's low volatility, represented by the beta of 0.30 and the potential EPS growth of 32.12% in the next five years. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
